Echo IQ Limited (ASX:EIQ)
Australia · Delayed Price · Currency is AUD 0.4700
+0.0650 (16.05%)
At close: Jan 22, 2026
Echo IQ Company Description
Echo IQ Limited engages in the provision of artificial intelligence (AI) diagnostics tool that enhance the diagnosis of structural heart disease in Australia.
It offers EchoSolv, provides an AI-powered risk assessment of structural heart disease, including aortic stenosis, diastolic dysfunction, and heart failure.
The company was formerly known as Houston We Have Limited and changed its name to EchoIQ Limited in December 2021.
Echo IQ Limited is based in Claremont, Australia.
Echo IQ Limited
| Country | Australia |
| Industry | Health Information Services |
| Sector | Healthcare |
| CEO | Dustin Haines |
Contact Details
Address: U5, 264 Stirling Hwy Claremont, Washington 6010 Australia | |
| Phone | 61 2 9159 3719 |
| Website | echoiq.ai |
Stock Details
| Ticker Symbol | EIQ |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000195430 |
| SIC Code | 7372 |
Key Executives
| Name | Position |
|---|---|
| Dustin Haines | Chief Executive Officer |
| Andrew Grover | Executive Chairman |
| Nianh Byrne | Finance Manager |
| Sam Dribin | Chief Technology Officer |
| Prof. David Playford | Chief Medical Advisor |
| Donald L. Fowler | President of Echo IQ USA |
| Deon Strydom | Chief Commercial Officer |
| Prof. Geoffrey A. Strange | Chief Research and Strategy Officer |
| Jessamyn Sarah Lyons AGIA, B.Com. | Company Secretary and Director |